The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Workplace and Insurance IssuesWorkplace and Insurance Issues
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Jul 24, 2012

hello, in worst case, if the eu-fta act is passed, would the indian generic companies stop producing ART for the poor nations? what would be the price and availability scenarios both in india and other poor countries? science and conscience will leave people dying? regards.

Response from Mr. Chambers

There is concern that the pending Free Trade Agreement between the European Union and India may impact the production of low cost HIV medications due to a proposed provision that could extend the patent life of the medications. The negotiations are continuing, but, at present the provision is still included in the proposed agreement. People involved in the negotiations are claiming they will have the agreement in place by the end of 2012.

There does appear to be a growing outcry from AIDS activists against this possibility. To learn more and join the growing chorus, there are several blogs and websites with articles about this. Rather than link them all, I suggest you do a browser search for "eu-fta India HIV".

Thanks for bringing this subject to my attention.


SSDI CDR question
insurance in usa for international student

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint